BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences:

• 2024 RBC Capital Markets Global Healthcare Conference, New York, NY
  May 14, 2024, fireside chat at 3:35 pm EDT
  Webcast

• BofA Securities 2024 Health Care Conference, Las Vegas, NV
  May 15, 2024, corporate presentation at 3:40 pm PDT
  Webcast

For more information, including available webcasts, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the event.

About Caribou’s novel next-generation CRISPR platform

CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T cell platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com. 

Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media:
Peggy Vorwald, PhD
This email address is being protected from spambots. You need JavaScript enabled to view it.